Lakefront Biotherapeutics reported EUR1.83M in Loan Capital for its fiscal quarter ending in September of 2026.





Loan Capital Change Date
argenx SE USD 36M 432K Jun/2026
AstraZeneca USD 28.8B 2.79B Sep/2026
Biogen USD 7.29B 1.7M Sep/2026
Genmab DKK 4.96B 28M Jun/2026
Gilead Sciences USD 23.82B 17M Sep/2026
GlaxoSmithKline GBP 21.7B 7.75B Sep/2026
GRIFOLS EUR 8.69B 1.52B Sep/2026
Hikma Pharmaceutical USD 1.49B 692M Dec/2025
Incyte USD 28.42M 994K Jun/2026
Merck EUR 10.34B 866M Sep/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 38.38B 893M Sep/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sanofi EUR 16.28B 1.63B Sep/2026
UCB EUR 2.18B 634M Dec/2025
Vertex Pharmaceuticals USD 3.5B 3.39B Sep/2026